Treatment effects in multi-centre randomised clinical trials

1 March 2019 - It is common for treatments to be evaluated in clinical trials that involve many sites or centres, ...

Read more →

Post-marketing modifications of drug labels for cancer drugs approved by the US FDA between 2006 and 2016 with and without supporting randomized controlled trials

11 April 2018 - Modifications in cancer drug indications, dosing, and related toxicities after FDA approval are common. It is unclear ...

Read more →

Finding RCTs of new drugs: searches in trial registries require specific adaptations

5 January 2018 - In their article in the Journal of Clinical Epidemiology, Marco Knelangen, Elke Hausner, Sibylle Sturtz, and ...

Read more →

Many FDA approved cancer drugs might lack clinical benefit

21 December 2017 - New research shows that less than half of the randomised controlled trials that support the approval of ...

Read more →

Mendelian randomisation

21 November 2017 - Mendelian randomisation uses genetic variants to determine whether an observational association between a risk factor and an ...

Read more →

Negative control outcomes: a tool to detect bias in randomised trials

27 December 2016 - Investigators have several design, measurement, and analytic tools to detect and reduce bias in epidemiological studies. One ...

Read more →